Schonfeld Strategic Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,706	Closed	-$249K	–	3407
2022 Q2	$249K	Buy	+1,706	New	+$218K	﹤0.01%	1772
2021 Q4	–	Sell	-4,700	Closed	-$653K	–	2858
2021 Q3	$653K	Sell	4,700 -1,300	-22%	-$162K	0.01%	1142
2021 Q2	$582K	Buy	+6,000	New	+$487K	0.01%	1123
2020 Q4	–	Sell	-13,525	Closed	-$879K	–	2045
2020 Q3	$879K	Buy	+13,525	New	+$886K	0.02%	733
2020 Q1	–	Sell	-11,361	Closed	-$619K	–	1716
2019 Q4	$619K	Sell	11,361 -85,139	-88%	-$4.22M	0.02%	666
2019 Q3	$4.03M	Buy	96,500 +90,900	+1,623%	+$3.84M	0.12%	192
2019 Q2	$245K	Sell	5,600 -5,000	-47%	-$282K	0.01%	834
2019 Q1	$546K	Sell	10,600 -182,000	-94%	-$7.86M	0.02%	666
2018 Q4	$7.12M	Buy	192,600 +96,300	+100%	+$3.47M	0.27%	92
2018 Q3	$3.62M	Buy	+96,300	New	+$3.54M	0.16%	182
2018 Q2	–	Sell	-117,919	Closed	-$3.04M	–	1109
2018 Q1	$3.04M	Buy	117,919 +96,525	+451%	+$2.89M	0.23%	130
2017 Q4	$577K	Buy	+21,394	New	+$589K	0.05%	429

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Schonfeld Strategic Advisors's BHVN Position: Q3 2022 in Review

Schonfeld Strategic Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 1,706 shares — an estimated $249K sold.

Schonfeld Strategic Advisors first reported a position in BHVN in Q4 2017 and held it in 12 quarters. The position peaked at $7.12M in Q4 2018. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Schonfeld Strategic Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 1,706 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $249K.
Schonfeld Strategic Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 12 quarters.
Schonfeld Strategic Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $7.12M in Q4 2018.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.